Two September 8, 2026 market reports forecast continued expansion across pharmaceutical services and biotechnology. Wissen Research projects the global pharmaceutical contract development and manufacturing organization (CDMO) market will grow from $191 billion in 2026 to $270.3 billion by 2031, representing a 7.2% compound annual growth rate, as pharmaceutical and biotechnology companies outsource development and manufacturing and demand rises for biologics, advanced therapies and complex therapeutics. ResearchAndMarkets.com projects the global multiomics market, which integrates genomic, transcriptomic, proteomic, metabolomic and epigenomic profiling, will increase from $3.18 billion in 2026 to $5.70 billion by 2031 at a 12.3% compound annual growth rate. Its growth is being supported by precision medicine, oncology, drug discovery, single-cell analysis, spatial omics, next-generation sequencing, mass spectrometry, artificial intelligence, machine learning and cloud bioinformatics. North America leads the CDMO market, Asia-Pacific is the fastest-growing CDMO region, and Asia Pacific is forecast to record the highest multiomics CAGR.